Pharma BD Deal Intelligence
Sanofi's ANKET expansion into B7-H3 for just $27M upfront looks cheap against the up-to-$1.42B ceiling, but the option component has already eroded: Sanofi terminated its exercised IPH67 license in 2025, leaving just one further ANKET option standing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay French biotech Innate Pharma 25 million euros upfront for rights to a B7-H3-directed natural killer cell engager and options on two more…
Sanofi has signed a second NK cell engager licensing deal with Innate Pharma, this time for a B7-H3-targeted asset along with options on up to two additional…
FY2025 update: IPH62 (B7-H3) ANKET remains under preclinical development; Sanofi to lead development, manufacturing and commercialization upon candidate…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Announced Dec 19, 2022 and effective Jan 25, 2023 after Hart-Scott-Rodino clearance, Sanofi licensed Innate Pharma's B7-H3-targeted NK cell engager program (IPH62) from the ANKET platform, with options on up to two additional ANKET targets. Innate received EUR 25M (~$27M) upfront against up to EUR 1.35B (~$1.42B) in development, regulatory and commercial milestones plus royalties. The lead B7-H3 asset (IPH62) remains partnered and in preclinical development, with Sanofi to assume all development, manufacturing and commercialization upon candidate selection. The option/expansion component has since eroded: Sanofi exercised an option in Dec 2023 to license a second solid-tumor NKCE (IPH67) but terminated that license (notice Oct 9, 2024; effective Jan 7, 2025), returning IPH67 rights to Innate. As of Innate's FY2024 report Sanofi retained one further ANKET option. The deal thesis holds for the lead B7-H3 asset, but the multi-target platform-expansion upside that underpinned the headline milestone ceiling is materially reduced.
600K US cases/yr · $135.0B Global oncology therapeutics market 2022 · ~$1.45B Total deal BD value (up to, incl. milestones + royalties)
The Sanofi-Innate B7-H3 NK cell engager program targets solid tumor indications where B7-H3 (CD276) is overexpressed across a broad spectrum of malignancies including non-small cell lung cancer (~236,000 U.S. cases annually), prostate cancer (~288,000), pancreatic adenocarcinoma (~64,000), and pediatric/adult brain tumors. B7-H3 is a B7-family checkpoint molecule expressed at low levels on normal tissues but markedly upregulated in 60-90% of NSCLC, prostate, and pancreatic tumors, making it one of the most validated tumor-associated antigens of the past five years. Commercial momentum sits in NSCLC and castration-resistant prostate cancer (CRPC) where existing standards include checkpoint inhibitor combos and PARP/AR-axis agents. The NK cell engager modality (Antibody-based NK Cell Engager Therapeutics, ANKET) is differentiated from T-cell engager bispecifics by leveraging innate immunity, theoretically narrowing cytokine release syndrome risk that has plagued CD3xTAA bispecifics in solid tumors. Pricing benchmarks for novel solid-tumor immunotherapies range $15K-25K per month WAC.
The B7-H3 competitive landscape is one of the most crowded emerging tumor antigen plays in immuno-oncology. Anti-B7-H3 ADCs are led by ifinatamab deruxtecan (I-DXd, MK-2400, Daiichi/Merck) in extensive-stage SCLC Phase 3 (IDeate-Lung01) and CRPC; vobramitamab duocarmazine (MGC018, MacroGenics/Synaffix) in mCRPC Phase 2/3; and DS-7300 derivatives. CD3xB7-H3 T-cell engagers include Janux's JANX008 (preclinical) and Y-mAbs' omburtamab (radiolabeled, FDA refusal letter 2022). The ANKET NK-cell engager class led by Innate is differentiated by NKp46/CD16/IL-2v scaffolds — Sanofi already paid $400M upfront for Innate's lead ANKET (IPH6101/SAR443579, CD123-targeted in AML) in 2022. Trispecific NK engagers are emerging from Affimed (AFM24 EGFRxNK) and Dragonfly Therapeutics (TriNKETs partnered with Bristol Myers and Merck). Sanofi's stack now spans hematologic and solid-tumor ANKETs, positioning Sanofi as the franchise leader in the NK engager modality.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Innate Pharma SA (this deal) | 2022 | $1.4B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Oncology deals